Adeline Lin Ph.D.

Adeline is an associate at Lightstone Singapore PTE. LTD. where she supports the team in evaluating new investment opportunities in the biopharmaceutical and medical device sectors.
Adeline was awarded the National Science Scholarship from the Agency for Science, Technology and Research (A*STAR) and received her B.Sc. from the University of Illinois, Urbana Champaign and her Ph.D. in Microbiology from Washington University, St Louis. Prior to joining Lightstone, Adeline was at A*STAR managing strategic research collaborations with industrial partners in the life sciences sector.

Hank Plain

Hank Plain is a General Partner of Lightstone Ventures. He also serves as a General Partner at Morgenthaler Ventures, which he joined in 2007 after more than 25 years in the pharma and medical device industry.

Mr. Plain began his career in 1980 with Eli Lilly. He left Lilly to become CEO of Perclose, where he led the company through a successful IPO and acquisition by Abbott Laboratories in 1999. Prior to becoming a venture capitalist, he co-founded eight medical device companies along with the team at The Foundry medical device incubator.

Mr. Plain serves on the boards of Earlens, Nuvaira, Moximed and Setpoint. He previously served on the boards of nine companies that were acquired – Claret Medical, Miramar Labs, Twelve Medical, Ardian, Access Closure, Acclarent, Cabochon, EPI and TransVascular.

Mr. Plain is Chairman of the Board of Trustees for the Naval Postgraduate School Foundation in Monterey, CA and the Future Citizens Foundation/First Tee of Monterey County.

Chris Christoffersen, Ph.D.

Chris was a Founding Partner of Lightstone Ventures and is currently a Special Partner. He focuses on biopharmaceutical investments out of the firm’s Boulder, CO, office. Chris joined Morgenthaler in 2001 and serves as a General Partner. His signature deals include Avidia (acquired by Amgen in 2006), Threshold (NASDAQ: THLD), Morphotek (acquired by Easai in 2007), FoldRx (acquired by Pfizer in 2010), and Nimbus Therapeutics/Apollo (partially acquired by Gilead in 2015). He serves on the boards of Adastra Pharmaceuticals, and previously on Nimbus. Chris brings to Lightstone more than 20 years of operations experience, having served as CEO and President of Ribozyme Pharmaceuticals (a/k/a Sirna Therapeutics; acquired by Merck for $1.2B), Senior Vice President of Research at SmithKline Beecham, Vice President of Discovery Research at The Upjohn Company, and President of Colorado State University.

Chris is a recognized thought leader in the field of biotechnology. He received an honorary Doctor of Law degree from Cornell College in 1983, the Outstanding Research of Year Award from the International Society of Quantum Biology in 1981, the W. E. Upjohn Award for contributions in biotechnology in 1988, and a Lifetime Achievement Award in 2003 from the Colorado Biosciences Association.

Jean George

Jean is a General Partner of Lightstone Ventures. She focuses on biopharmaceutical and medical device investments out of the firm’s Boston office, where she also serves as a General Partner of Advanced Technology Ventures (ATV). Her representative investments include Acceleron Pharma (NASDAQ: XLRN), Calithera Biosciences (NASDAQ: CALA), Catabasis Pharmaceuticals (NASDAQ: CATB), Cyteir Therapeutics, Disarm Therapeutics, Flex Pharma (NASDAQ: FLKS), Five Prime Therapeutics (NASDAQ: FPRX), Gemini Therapeutics, Hypnion (acquired by Eli Lilly), Locana Therapeutics, Portola Pharmaceuticals (NASDAQ: PTLA), Proteolix (acquired by Onyx Pharmaceuticals), Tizona Therapetics, Verastem (NASDAQ: VSTM), and Zeltiq Aesthetics (NASDAQ: ZLTQ).

Jean has been featured on the Forbes Midas List and was previously a member of the Scientific Advisory Board for the Massachusetts Life Sciences Center. Prior to LSV and ATV, Jean worked for BancBoston Ventures and led its life sciences investments in Neurometrix (NASDAQ:NURO), Ironwood Pharmaceuticals (NASDAQ: IRWD), NuGenesis Technologies (acquired by Waters) and Syntonix Pharmaceuticals (acquired by Biogen/Idec).

She has been in the biopharmaceutical industry for over 30 years, including 10 years with Genzyme Corporation, where she held a variety of operational roles in marketing, product development, and business development, including Vice President of Global Sales and Marketing. She also was Vice President and Founder of Genzyme’s Tissue Repair Division.  Previously, Jean spent six years working in chemistry and bioresearch.

Mike Carusi

Mike is a General Partner and Team Leader of Lightstone Ventures (LSV) and focuses on investments in the biopharmaceutical and medical device sectors. He is based in the firm’s Menlo Park, CA office, where he also serves as a General Partner at Advanced Technology Ventures (ATV). His representative investments include Altura Medical (acquired by Lombard), Ardian (acquired by Medtronic), Cala Health, EndoGastric Solutions, Gynesonics, MediSix Therapeutics, MicroVention (acquired by Terumo), Nuvaira, Plexxikon (acquired by Daiichi Sankyo), PowerVision (acquired by Alcon), Second Genome, Tallac Therapeutics, and Willow.

Featured on the Forbes Midas List of top technology and life science investors, Mike is a recognized thought leader in the industry and a frequent speaker at healthcare conferences. He serves as an Adjunct Professor at the Tuck School of Business Administration at Dartmouth College. In addition, Mike has been heavily involved with several programs at Stanford University including the Stanford Biodesign Program and, more recently, the Stanford Center for Clinical and Translational Research and Education (Spectrum). Lastly, Mike served as a Director on the National Venture Capital Association (NVCA) Board of Directors and remains active in helping to shape policy affecting both innovation and healthcare.

Earlier in his career, Mike served as a Director of Business Development for Inhale Therapeutic Systems (now Nektar Therapeutics, NASDAQ: NKTR), a venture-backed pulmonary drug delivery company that went public in 1994. At Inhale, Mike led partnering activities with a number of pharmaceutical and biotechnology companies in the U.S., Europe, and Japan. Mike also was a Principal at The Wilkerson Group, a leading management consulting firm focused exclusively on healthcare. At The Wilkerson Group, Mike helped establish the firm’s offices in London and San Francisco.

Jason Lettmann

Jason Lettmann is a General Partner of Lightstone Ventures and focuses on investments in the biopharmaceutical and medical technology sectors. Jason also is a General Partner on the Life Science team at Morgenthaler Ventures and brings over 15 years of operating and venture experience in the life sciences. He currently serves on the Board of Directors of ALX Oncology, Carrick Therapeutics, Cerevance, FIRE1, Relievant Medsystems, and Second Genome. Jason served as the CEO of Promedior and led the company through its sale to Roche in 2020 as well as led the firm’s investments and served as a Director of Ra Pharmaceuticals (acquired by UCB) and Vapotherm (NASDAQ: VAPO). Jason also established Lightstone’s Europe office in 2014 located in Dublin, Ireland, to expand the firm’s investment activities to Europe and currently serves as Director of Lightstone Capital Management Ireland Ltd.

Before joining Morgenthaler in 2009, Jason was a Vice President at Split Rock Partners where he focused on early-stage venture investments in the life sciences. During his time at Split Rock, Jason was actively involved with the firm’s investment in Ardian (acquired by Medtronic), Cabochon Aesthetics (acquired by Ulthera), Atritech (acquired by Boston Scientific), Entellus Medical (acquired by Stryker), Evalve (acquired by Abbott), and Transcend Medical (acquired by Alcon). Jason was also previously a co-founder and on the Board of Tarsus Medical before its acquisition by Integra Life Sciences in 2013.